Kura Oncology Inc. held a presentation focusing on their investigational menin inhibitor, Ziftomenib, targeted at treating relapsed/refractory and newly diagnosed acute myeloid leukemia $(AML.AU)$. The presentation highlighted the positive results from the Phase 2 KOMET-001 trial, which led to a New Drug Application (NDA) for Ziftomenib. This NDA has been granted Priority Review with a Prescription Drug User Fee Act (PDUFA) target action date set for November 30, 2025. The presentation also discussed the Ziftomenib Global Development Plan, including the KOMET-017 Phase 3 clinical trials and the market opportunity for newly diagnosed NPM1-m and KMT2A-r AML patients. Key opinion leaders such as Dr. Harry Erba and Dr. Ghayas C. Issa participated in the event. You can access the full presentation through the link below.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。